Back to search results

Deep TMS for Heavy Drinking in Alcohol Use Disorder

This study is testing the safety and effectiveness of BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for reducing heavy drinking in people with Alcohol Use Disorder (AUD). Deep TMS is a device that uses magnetic pulses. You could be between 18 and 86 years old and have been diagnosed with moderate to severe AUD to join. The study will compare alcohol use in two groups: one receiving Deep TMS and another receiving a sham (inactive) treatment. The main goal is to see if Deep TMS helps more people achieve zero heavy drinking days over 2-4 months. The current recruitment status is unclear.

Study design
This is a double-blind, randomized, controlled, multi-center trial with 186 planned participants. It compares two groups: one receiving Deep TMS and another receiving a sham treatment.
What's involved
Participants will have 30 treatment sessions over 15 visits during a 3-5 week acute phase, followed by one treatment session per week during a maintenance and follow-up phase.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for measuring heavy drinking days is at 2-4 months after treatment. The study includes a maintenance treatment and follow-up phase, but the exact duration of follow-up is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07216872

Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment and Reduction of Heavy Drinking in Individuals With of Alcohol Use Disorder (AUD)

Recruiting
NAAges 18–86InterventionalTreatment
Brainsway
~186 participants
Updated 2026-07-17 on ClinicalTrials.gov
What's tested:Deep TMS (DTMS)Sham (No Treatment)

At a glance

Recruiting sites
9 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Difference in proportion of patients who attain zero (0) heavy drinking days
Measured over 2-4 months

Conditions

Alcohol Use Disorder
Alcoholism
Alcohol Abuse
Alcohol Dependence
Alcohol Abuse/Dependence
Alcohol Addiction

Explore related trials

Alcohol use disorder

Where it's being run

9 sites across 9 states
Alabama1
California1
Florida1
Illinois1
New York1
Ohio1
Oregon1
West Virginia1

Who to contact

Ahava Stein
[email protected]
+972-9-7670002
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Any condition likely to be associated with increased intracranial pressure
Space occupying brain lesion
History of cerebrovascular accident
Transient ischemic attack within two years
Cerebral aneurysm
Dementia
Mini Mental State Exam score of less than or equal to 24
Parkinson's disease
Huntington's chorea
Multiple sclerosis 12. Subjects suffering from significant hearing loss. 13. Previous treatment with TMS within one year. 14. Subject's motor threshold cannot be located or is \> 58%. 15. Participation in another clinical investigation in which a device or drug has been used within 4 weeks of screening. 16. If participating in psychotherapy, subject is not in stable treatment for at least 3 months prior to entry into the study or anticipates a change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the rTMS trial. 17. Known or suspected pregnancy or planning to become pregnant. 18. Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse.

What this trial measures

  • Difference in proportion of patients who attain zero (0) heavy drinking days2-4 months

    The difference in the proportion of patients who attain zero (0) heavy drinking days in the Treatment group versus the Sham control group in months 2, 3 and 4 following initiation of the Acute Phase, based on TLFB reporting and supportive PEth results. Month 1 is considered a "Grace Period" as this is the time during which the full treatment dose of the Acute Phase is being delivered.